Respiratory syncytial virus vaccination during pregnancy for improving infant outcomes-Reference-Cited by-同舟云学术

Respiratory syncytial virus vaccination during pregnancy for improving infant outcomes

Published:2024-05-02 Issue:5 Volume:2024 Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

Phijffer Emily WEM¹,de Bruin Odette²³,Ahmadizar Fariba³,Bont Louis J⁴,Van der Maas Nicoline AT⁵,Sturkenboom Miriam CJM³,Wildenbeest Joanne G⁴,Bloemenkamp Kitty WM⁶

Affiliation:

1. Department of Paediatric Infectious Diseases and Immunology; Wilhelmina Children's Hospital, University Medical Center Utrecht; Utrecht Netherlands

2. Department of Obstetrics, Division Woman and Baby; Wilhelmina Children's Hospital, University Medical Center Utrecht; Utrecht Netherlands

3. Department of Data Science & Biostatistics, Julius Global Health; University Medical Center Utrecht; Utrecht Netherlands

4. Department of Paediatric Infectious Diseases and Immunology; Wilhelmina Childrens Hospital, University Medical Center Utrecht; Utrecht Netherlands

5. Centre for Infectious Disease Control; National Institute for Public Health and the Environment; Bilthoven Netherlands

6. Department of Obstetrics, Division Woman and Baby; Wilhelmina Childrens Hospital, University Medical Center Utrecht; Utrecht Netherlands

Publisher

Wiley

Reference72 articles.

1. Safety and immunogenicity of an investigational respiratory syncytial virus vaccine (RSVPreF3) in mothers and their infants: a phase 2 randomized trial;Bebia;Journal of infectious diseases,2023

2. Study of safety, reactogenicity and immunogenicity of GlaxoSmithKlineaâ‚¬â„¢s (GSK)Respiratory Syncytial Virus (RSV)maternal unadjuvanted vaccine in healthy pregnant women (aged 18 to 40 years) and their infants trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2019-001991-12-ES

3. Study of safety, reactogenicity and immunogenicity of glaxosmithkline's (GSK)respiratory syncytial virus (RSV)maternal unadjuvanted vaccine in healthy pregnant women (aged 18 to 40 years) and their infants clinicaltrials.gov/show/nct04126213

4. Dieussaert I Dormitzer PR Kim JH Luik S Seidl C Stegmann JU 126. Preterm birth signal in a maternal immunization study with a respiratory syncytial virus prefusion f protein vaccine candidate Abstract Booklet RSVVW'23 2023

5. A phase III double-blind study to assess safety and efficacy of an RSV Maternal unadjuvanted vaccine, in pregnant women and infants born to vaccinated mothers trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2020-001355-40-FI

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Safety and Efficacy of Antiviral Drugs and Vaccines in Pregnant Women: Insights from Physiologically Based Pharmacokinetic Modeling and Integration of Viral Infection Dynamics;Vaccines;2024-07-16

2. Respiratory syncytial virus (RSV) prevention: perception and willingness of expectant parents in the Netherlands;2024-06-23

3. Impact of Nirsevimab Immunization on Pediatric Hospitalization Rates: A Systematic Review and Meta-Analysis (2024);Vaccines;2024-06-08